1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. 1V209 can be conjugated with various polysaccharides to improve its water solubility, and enhance its efficacy, and maintain low toxicity.

Product information

CAS Number: 1062444-54-5

Molecular Weight: 359.34

Formula: C16H17N5O5

Chemical Name: 4-{[6-amino-2-(2-methoxyethoxy)-8-oxo-8,9-dihydro-7H-purin-9-yl]methyl}benzoic acid

Smiles: COCCOC1N=C2C(NC(=O)N2CC2C=CC(=CC=2)C(O)=O)=C(N)N=1

InChiKey: ATISKRYGYNSRNP-UHFFFAOYSA-N

InChi: InChI=1S/C16H17N5O5/c1-25-6-7-26-15-19-12(17)11-13(20-15)21(16(24)18-11)8-9-2-4-10(5-3-9)14(22)23/h2-5H,6-8H2,1H3,(H,18,24)(H,22,23)(H2,17,19,20)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 83.33 mg/mL (231.90 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

1V209 (0.1-10 μM) treatment significantly stimulates TNFα production in RAW246.7 cells. 1V209 (18 hours) treatment increases IL-6 production comparain bone marrow derived dendritic cells.

In Vivo:

The intravenous (IV) administration of the formulation to mice bearing 4T1 breast cancer tumors results in nanoparticle accumulation in tumors, reduction in primary tumor growth, and inhibition of lung metastases, as compared to saline-treated animals. Mice administered 1V209 experience significantly increases plasma levels of proinflammatory cytokines IL-6, IP-10, and MCP-1 at 2 h following IV administration.

Products are for research use only. Not for human use.